Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 16/20 | 0.41 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29517349 | 1.00 | PTK2 (0.41) | PTK2ADKKDM4EPTGDR2ALDH1A1 | |
| SCHEMBL29517219 | 0.81 | PTK2 (0.59) | PTK2 | |
| SCHEMBL22658779 | 0.81 | PTK2 (0.59) | PTK2 | |
| SCHEMBL22658823 | 0.80 | PTK2 (0.34) | PTK2ADKKDM4EPTGDR2ALDH1A1 | |
| SCHEMBL29517167 | 0.80 | PTK2 (0.34) | PTK2ADKKDM4EPTGDR2ALDH1A1 | |
| SCHEMBL29517496 | 0.78 | PTK2 (0.45) | PTK2 | |
| SCHEMBL29517226 | 0.78 | PTK2 (0.45) | PTK2 | |
| SCHEMBL22658562 | 0.77 | PTK2 (0.46) | PTK2 | |
| SCHEMBL29517228 | 0.77 | PTK2 (0.46) | PTK2 | |
| SCHEMBL22658808 | 0.75 | PTK2 (0.62) | PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3965803-B1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA FARBER CANCER INST INC (US) | 2025-08-20 | — | — | EP | disclosed |
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20220242882-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-08-04 | — | — | US | disclosed |
| WO-2020231726-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365696-B2 | Small-molecule focal adhesion kinase (FAK) inhibitors | PTK2, CTTN, TNK2 | PTK2 1/4885ADK 1045/4885KDM4E 3762/4885 |
| US-20220242882-A1 | SMALL-MOLECULE FOCAL ADHESION KINASE (FAK) INHIBITORS | PTK2, CTTN, TNK2 | PTK2 1/4885ADK 1045/4885KDM4E 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.